References
- Hirsch I B. Insulin analogues. N Engl J Med 2005; 352: 174–183
- Barnett A H. A review of basal insulins. Diabet Med 2003; 20: 873–885
- Poyhonen-Alho M, Ronnemma T, Saltevo J, Ekbald U, Kaaja R. Use of insulin glargine during pregnancy. Acta Obstet Gynecol 2007; 86: 1171–1174
- Price N, Bartlett C, Gillmer. Use of insulin glargine during pregnancy: a case-control pilot study. BJOG 2007; 114: 453–457
- Gallen I W, Jaap A, Roland J M, Chirayath. Survey of glargine use in 115 pregnant women with type 1 diabetes. Diabet Med 2008; 25: 165–169
- Woolderink J M, van Loon A J, Storms F, de Heide L, Hoogenberg K. Use of insulin glargine during pregnancy in seven type 1 diabetic women. Diabetes Care 2005; 28: 2594–2595
- Torlone E, Gennarini A, Ricci N B, Bolli G B. Successful use of insulin glargine during entire pregnancy until delivery in six type 1 diabetic women. Eur J Obstet Gynecol Reprod Biol 2007; 132: 238–239
- Lapolla A, Dalfra M G, Fedele D. Insulin therapy in pregnancy complicated by diabetes: are insulin analogs a new tool?. Diabetes Metab Res Rev 2005; 21: 241–252
- Carpenter M, Coustan D. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol 1982; 144: 768–773
- ACOG Practice Bulletin. Gestational diabetes. September 2001, Number 30
- Alexander G R, Himes J H, Kaufman R B, Mor J. A United States national reference for fetal growth. Obstet Gynecol 1996; 87: 163–168
- White P. Classification of obstetric diabetes. Am J Obstet Gynecol 1978; 130: 228–230
- Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time action profile of the long acting insulin analogue insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23: 644–649
- Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli G B. Pharacokinetics and pharmacodynamics of subcutaneous injection of long acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142–2148
- Kurtzhals P, Schäffer L, Sørensen A, Kristensen C, Jonassen I, Schmid C, Trub T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999–1005
- Hofmann T, Horstmann G, Stammberger I. Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits. Int J Toxicol 2002; 21: 181–189
- Greene M F. Prevention and diagnosis of congenital anomalies in diabetic pregnancies. Clin Perinatol 1993; 20: 533–547, Presented at the 56th Annual Clinical Meeting of The American College of Obstetricians and Gynecologists. New Orleans, Louisiana 3–7 May 2008